FDA approved Yescarta axicabtagene ciloleucel (KTE-C19) from the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD) to treat relapsed or refractory large B cell lymphoma after two or more lines of systemic
Read the full 332 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury